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Abstract
Whereas detrimental effects of vitamin D deficiency are known over century, the effects of vitamin D receptor activation by
1,25(OH)2D3, the principal hormonal form of vitamin D, on the growing bone and its growth plate are less clear. Currently,
1,25(OH)2D3 is used in pediatric patients with chronic kidney disease and mineral and bone disorder (CKD-MBD) and is
strongly associated with growth retardation. Here, we investigate the effect of 1,25(OH)2D3 treatment on bone
development in normal young rats, unrelated to renal insufficiency. Young rats received daily i.p. injections of 1 mg/kg
1,25(OH)2D3 for one week, or intermittent 3 mg/kg 1,25(OH)2D3 for one month. Histological analysis revealed narrower tibial
growth plates, predominantly in the hypertrophic zone of 1,25(OH)2D3-treated animals in both experimental protocols. This
phenotype was supported by narrower distribution of aggrecan, collagens II and X mRNA, shown by in situ hybridization.
Concomitant with altered chondrocyte maturation, 1,25(OH)2D3 increased chondrocyte proliferation and apoptosis in
terminal hypertrophic cells. In vitro treatment of the chondrocytic cell line ATDC5 with 1,25(OH)2D3 lowered differentiation
and increased proliferation dose and time-dependently. Micro-CT analysis of femurs from 1-week 1,25(OH)2D3-treated group
revealed reduced cortical thickness, elevated cortical porosity, and higher trabecular number and thickness. 1-month
administration resulted in a similar cortical phenotype but without effect on trabecular bone. Evaluation of fluorochrome
binding with confocal microscopy revealed inhibiting effects of 1,25(OH)2D3 on intracortical bone formation. This study
shows negative effects of 1,25(OH)2D3 on growth plate and bone which may contribute to the exacerbation of MBD in the
CKD pediatric patients.
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Introduction
During childhood, the skeleton undergoes rapid structural
adaptations to the growing body demands, manifested by changes
in the bone mineral composition, cortical and trabecular architec-
ture and altered mechanical properties. Bone mass acquisition is
orchestrated by a variety of factors ranging from genetic
determinants and nutritional influences, to the hormonal balance,
including classical regulation of mineral homeostasis by vitamin D
[1,2]. Vitamin D is obtained from dietary sources and is synthesized
in the skin by photoconversion of 7-dehydrocholesterol to vitamin
D3,which subsequently undergoes two majormodifications. First,it
is metabolized in the liver to produce the circulating form 25-
hydroxyvitamin D3 (25(OH)D3, calcidiol), which is later converted
in the kidney and other tissues including bone by 1a-hydroxylase to
generate the active form 1,25-hydroxyvitamin D3 (1,25(OH)2D3,
calcitriol). 1,25(OH)2D3 is the principal hormonal form of vitamin
D which binds to vitamin D receptor (VDR), exerting a wide range
of biological responses [1,2].
Whereas detrimental effects of vitamin D deficiency on bone
growth have been known over a century, the direct effects of VDR
activation on the growth plate are still a matter of investigation.
Analysis of transgenic VDR or 1a-hydroxylase null mice revealed
phenotypic abnormalities characteristic of vitamin D-dependent
rickets, with decreased bone mineralization, growth retardation
and aberrant growth plate development after weaning. Impaired
apoptosis of hypertrophic chondrocytes, with ordinary prolifera-
tion, was demonstrated to cause the significant widening and
disorganization of the epiphyseal growth plates [3]. These
phenotypes could largely be corrected by rescue supplementation
of dietary calcium and phosphate, suggesting a primary systemic
role of 1,25(OH)2D3 in intestinal calcium absorption [4,5]. In
contrast, transplantation of VDR null bone into wild-type mice
resulted in increased bone mass and vice versa, transplantation of
wild-type bone into VDR null mice developed osteopenia,
implying a direct inhibitory role of 1,25(OH)2D3 in osteogenesis
[6]. To support these data, conditional VDR inactivation in
growth plate chondrocytes has been shown to reduce vascular
invasion and osteoclast numbers leading to increased trabecular
bone mass [7]. Two additional transgenic mice models with
chondrocytes-specific 1a-hydroxylase ablation or overexpression,
revealed a ‘‘mirror image’’ growth plate phenotype with increased
hypertrophic zone width, reduced osteoclastogenesis and delayed
angiogenesis in the former, while decreased hypertrophic zone
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the later, further supporting the paracrine role 1,25(OH)2D3 in the
process of endochondral ossification [8].
Besides its physiological role, the pharmacological influence of
1,25(OH)2D3 on bone development in pediatric patients is not
fully understood. In the clinical settings, administration of
1,25(OH)2D3 is currently used as a standard of care treatment
combating both 1,25(OH)2D3 deficiency and secondary hyper-
parathyroidism in children with chronic kidney disease-mineral
and bone disorder (CKD-MBD) [9]. In the pediatric patients,
diminished renal function is commonly accompanied by a
disturbed bone metabolism, reduced linear growth and the
presence of ectopic soft tissue calcifications [9,10]. Despite its
widespread use, accumulating evidence points towards severe side
effects and chronic toxicity associated with active vitamin D
treatment [10,11,12]. Observational studies suggest that chronic
use of 1,25(OH)2D3 is strongly associated with suppression of PTH
and development of adynamic bone disease (ABD), characterized
by low bone turnover and diminished osteoblast and osteoclast
activities, in children with renal insufficiency [9,10]. Clinical
studies performed in children on peritoneal dialysis treated for 12
months with intermittent calcitriol therapy and calcium salts as
phosphate binders, demonstrated diminished linear growth and
induction of ABD, accompanied by significant reduction in PTH
and episodes of hypercalcemia [13,14,15]. Linking bone and
cardiovascular health, both ABD and 1,25(OH)2D3 were reported
to increase the occurrence of vascular calcification (VC), known as
a leading factor of mortality in CKD patients [11,16]. The risk for
cardiovascular complications exhibits a biphasic curve, with
highest risk involving vitamin D deficiency, uncontrolled hyper-
parathyroidism and high bone turnover, on one hand, and vitamin
D-induced low PTH and ABD on the other hand [11,17].
In attempt to understand the role of vitamin D in CKD-MBD
state, several studies examined the effect of 1,25(OH)2D3
treatment on growth plate and bone development in renal failure
animal models. Daily or intermittent treatment with 1,25(OH)2D3
for a period of 4 weeks of 5/6 nephrectomized weanling rats with
secondary hyperparathyroidism was shown to increase the
markers of growth plate chondrocytes proliferation [18]. Short-
term treatment of uremic rats with 1,25(OH)2D3 resulted in a
reduced number of chondro-osseous junction chondroclasts
compared to uremic control [19]. Examination of bone micro-
architecture in nephrectomized growing rats revealed significantly
altered bone parameters, including increased trabecular thickness,
reduced cortical thickness and increased porosity, which were
aggravated by daily administration of 1,25(OH)2D3 [20]. Treat-
ment with calcimimetic VDR analogues in a similar uremic rat
model were also demonstrated to affect bone formation reducing
osteoid surface and increasing bone resorption [21]. Collectively,
these studies suggest that active vitamin D influences growth plate
and bone formation in the young skeleton and may contribute to
the diminished growth in CKD-MBD children.
At present, limited data is available on the direct effects of
1,25(OH)2D3 in bone tissue under physiological conditions,
separate from renal insufficiency. In the current study we
investigate the influence of continuous 1-week and intermittent
1-month administration of 1,25(OH)2D3 on growth plate and bone
development in normal young rats.
Materials and Methods
Cell culture and treatment with 1,25(OH)2D3
ATDC5 cell line [22] was cultured in DMEM/F-12 medium
(Bet-Haemek) supplemented with 5% FBS, 1% Insulin-transferrin-
sodium selenite (Sigma-Aldrich), penicillin (100 units/mL) /
streptomycin (0.1 mg/mL), and 4 mM L-Glutamine. 1,25(OH)2D3
(Sigma-Aldrich) was dissolved in ethanol and stored as 41.6 mg/mL
(100 mM)s t o c ka t220Cuuntil use. For differentiation experiments, cells
were seeded at initial density of 56 10
4 cells / well in 12 well plates and
treated the following day with 1–30 nM 1,25(OH)2D3 dissolved in
normal medium or same volume of ethanol dissolved in medium, as
control. Cells were treated twice 1-week for a period of 1, 7, 14, and 21
days [22]. Cells were observed under inverted Nikon Eclipse TS100
microscope equipped with DS-F1camera control unit.
In vitro proliferation and differentiation of ATDC5
Throughout ATDC5 differentiation and treatment with
1,25(OH)2D3 experiment cell media were collected and stored at
220Cu. Staining with Alizarin Red, Alcian Blue, and Alkaline
Phosphatase (ALP) and MMP zymography were performed as
described previously [22,23,24]. Secreted ALP activity was
measured by adding 100 mL of 0.5 mM pNPP substrate dissolved
in basic buffer: 0.1 M Tris-HCl, 0.1 M NaCl, 0.05 M MgCl2,
pH 9.5, to 100 mL of cell medium in 96 well plate and incubating
30 min at RT, protected from light. Hydrolyzed pNPP was
assessed by absorbance at 405 nm. For secreted GAG detection
100 mL of DMB solution (16 g 1,9-dimethylmethylene blue (DMB)
dissolved in 55 mmol/L formic acid, pH 3.3) solution was added
to 100 mL of cell medium in 96 well plate, incubated 2 hrs at RT
and binding complex absorbance was read at 595 nm (non-
complexed signal). DMB-GAG complex formation was calculated.
Bone Gla Protein (BGP, also known as osteocalcin) levels in cell
media were identified by ELISA using Mouse Osteocalcin EIA kit
(Biomedical Technologies), according to manufacturer’s instruc-
tions. Metabolic activity was measured using XTT kit (Biological
Industries) according to manufacturer’s instructions.
Gene quantification with real-time PCR
RNA was extracted using TRI-reagent (Sigma-Aldrich) accord-
ing to manufacturer’s instructions. 1 mg of total RNA was reversed
transcribed using High Capacity cDNA kit (Applied Biosystems).
cDNA was diluted 1:25 and used for real-time PCR using
Platinum SYBR Green qPCR SuperMix-UDG with ROX
(Invitrogen) to measure gene expression using specific primers
sets: Collagen typeII(f) GAACAGCATCGCCTACCTGG, Colla-
gen typeII(r) TGTTTCGTGCAGCCATCCT; Sox9(f) GCATC-
TGCACAACGCGG, Sox9(r) CTCGTTCAGCAGCCTCCAG;
Runx2(f) AGGCACAGACAGAAGCTTGATG, Runx2(r) GCG-
ATCAGAGAACAAACTAGGTTTAGA; MMP2(f) ATTGACG-
CTGTGTATGAGGCC, MMP2(r) ACTCATTCCCTGCGAA-
GAACA; MMP9(f) AGCCCCTGCTCCTGGCTCTC, MMP9(r)
CTGCCAGCTGGGTGTCCGTG; GAPDH(f) TGACGTGCC-
GCCTGGAGAAA, GAPDH(r) AGTGTAGCCCAAGATGCC-
CTT. Dissociation curves were ran following Real-Time PCR
reactions to insure the detection of the desired amplicon and
exclude the presence of contaminating products. Amplification
was carried out using 7300 Fast Real-Time PCR System (Applied
Biosystems). Gene expression was normalized to GAPDH and the
data were analyzed using comparative 2
2DDCt method [25].
Animal experiments
The studies were approved by the Hebrew University of
Jerusalem Animal Care and Use Committee, Ethics number: AG-
09-12147-2. Male Sprague-Dawly rats (75 g, 4 weeks old) were
purchased from Harlen Labratories (Rehovot, Israel) and fed a
normal chow diet. Two experimental schedules were performed,
one week experiment and one month experiment. For a one week
experiment rats were randomly allocated into two groups: (1)
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for 7 days (n=6); (2) received i.p. injections of 1 mg/kg
1,25(OH)2D3 in saline, daily for 7 days (n=6). For a one month
experiment: (1) received i.p. injections of 2.4% (v/v) ethanol in
saline vehicle three times a week for 30 days (n=6); (2) received
i.p. injections of 3 mg/kg 1,25(OH)2D3 in saline, three times a
week for 30 days (n=6). The total volume of injection was 100 mL
per 100 mg of rat body weight. In the clinical settings, secondary
hyperparathyroidism associated with moderate-to-severe CKD-
MBD in pediatric patients is managed with doses reaching
0.025 mg/kg daily (The Merck Manual). We have chosen to
administer about 40 times higher dose due the following reasons.
First, both of our experiments were designed to span a
considerably shorter time-frame, in comparison to chronic
1,25(OH)2D3 treatment practiced in CKD-MBD patients, where
drug and its effects may be accumulated over time. Second, during
the allometric dose translation from animals to humans, in
addition to body weight (BW), Km factor representing BW (kg)
divided by body surface area (BSA, m
2) of both species is
commonly taken into account. BSA has been previously shown to
correlate with several parameters including oxygen utilization,
caloric expenditure, basal metabolism, blood volume, circulating
plasma proteins, and renal function [26]. Thus, according to the
Food and Drug administration recommendations, dose given to
rats should be about 6.2 times higher than dose given to humans
[26]. To accommodate these two notions we decided to administer
a dose higher than normally given to pediatric CKD-MBD
patients, which in our view serves a better representation of the
clinical picture. Both groups in one week experiment also received
i.p. injections of mineral binding fluorochromes, 40 mg/kg calcein
on day 2 and 20 mg/kg alizarin complexon on day 5. At the end
of the experiment the animals were anesthetized by Isoflurane and
killed by cervical dislocation. Tibiae were removed, decalcified
and embedded in paraffin blocks for histological analysis, femurs
were frozen at 220Cu until subsequent micro-CT analysis.
Micro-CT
The region of proximal metaphysis to mid- diaphysis of all
femurs , was scanned with a Skyscan 1174 X-ray computed
microtomograph scanner (Skyscan, Aartselaar Belgium), equipped
with a CCD detector. Images were obtained by 50 kV X-ray tube
voltage and 800 mA current. Specimens from the 7-day calcitriol
experiment were scanned using 0.25 mm aluminum filter, at
3500 ms exposure time, and at 13.8 pixel size resolution. For
samples belonging to the 1-month calcitirol experiment 0.5 mm
aluminum filter, 4000 ms exposure time and 13.8 pixel size
resolution were used. For each specimen, a series of 900 projection
images were obtained with a rotation step of 0.4u, averaging 2
frames, for a total 360u rotation. Flat field correction was
performed at the beginning of each scan for a specific zoom and
image format. A stack of 2D X-ray shadow projections was
reconstructed to obtain images using NRecon software (Skyscan),
and subjected to the morphometric analysis using CTAn software
(Skyscan). During reconstruction, dynamic image range, post-
alignment value, beam hardening and ring-artifact reduction were
optimized for each experimental set. Analysis of the diaphyseal
cortical region 200 slices, corresponding to 2.764 mm were
chosen. Global greyscale threshold levels for the cortical region
were between 100 and 255 were selected. For the trabecular
region a total of 150 slices, corresponding to 2.073 mm were
selected, and adaptive grayscale threshold levels between 40 (1-
week experiment) and 60 (1-month experiment) to 255were used.
Morphometric analysis was based on the 2-D and 3-D internal
CTAn plug-ins. 3-D images (CTM file format) were constructed
from cortical and trabecular regions of interest, utilizing Marching
Cubes 33 algorithm in CTVol software [27].
Histology and immunohistochemistry
Tibiae were fixed overnight in 4% paraformaldehyde (Sigma-
Aldrich) in PBS at 4uC and subjected to 3 weeks of decalcification
in 0.5 M EDTA, pH 7.4. Following dehydration in graded
ethanol solutions and histoclear (Bar-Naor), tissue was embedded
in Paraplast, cut into 5 mm sections and mounted on Superfrost
slides (Thermo Scientific). For Safranin O staining, 0.1% Safranin
O (Sigma) solution was used. Growth plate total width and areas
width were measured using ImageJ software. For that, total growth
plate was visually separated into two areas, based on morpholog-
ical distinctions: 1. Proliferative zone, including columnar
chondrocytes and intense orange (Safranin O stained) extracellular
matrix; 2. Hypertrophic zone, including swollen mature, hyper-
trophic and terminally differentiated chondrocytes, characterized
by low extracellular matrix volume. In each zone, 7 vertical
(perpendicular to chondro-osseous junction) lines were drawn
throughout the growth plate and width was calculated as an
average of these 7 measurements. For immunohistochemistry,
sections were deparaffinized in xylene and washed twice with
ethanol. Endogenous peroxidase activity was blocked with 0.3%
H2O2 (Merck) in methanol for 30 min. Sections were rehydrated
through a graded series of ethanol solutions, rinsed in PBS+T and
blocked with 3% goat serum in PBS+T for 1 hr. Specific
antibodies were diluted in 3% goat serum in PBS+T and
incubated for 1–2 hrs. For PCNA immunostaining a pair of
primary mouse monoclonal anti-PCNA antibody 1:200 (Dako)
and secondary goat anti-mouse 1:400 (Jackson ImmunoResearch)
was used. HRP activity was measured using DAB substrate
(Sigma-Aldrich). Staining was observed under Nikon Eclipse E400
microscope equipped with Olympus D71 camera and cell‘A
software [28].
Probe preparation and in-situ hybridization
BlueScript constructs containing Collagen type II, Aggrecan,
Collagen type X were kindly provided by Dr. Eliezer Zeltzer.
Sense and antisense digoxigenin-labeled RNA probes were
transcribed using either T7 or T3 primers using DIG labeling
kit (Roche). Hybridization of 5 mm paraffin-embedded sections
and visualization with alkaline phosphatase–coupled anti-digox-
igenin antibodies and indolylphosphate-nitroblue tetrazolium
(BCIP/NBT) substrate were performed. Parallel sections were
Figure 1. 1-week continuous administration of 1,25(OH)2D3 induces chondrocyte proliferation and compresses chondrocytes
maturation zone in young rats. 4 weeks old male Spague Dawley rats received daily i.p. injections of 1 mg/kg 1,25(OH)2D3 (n=6, VD) or vehicle
(n=6, Ctr) for a period of 7 days. (A) Safranin O staining of proximal tibial growth plates. Arrows indicate reduced hypertrophic zone width in
1,25(OH)2D3-treated compared to the control group. (B) Width measurements of total growth plate, proliferative zone, and hypertrophic zone. (C)
Percent of PCNA positive proliferating cells out of total proliferating cell count. (D) Immunhistochemistry of PCNA positive proliferating cells. (E) In-
situ hybridization (ISH) of collagen type II mRNA. (F) ISH of aggrecan mRNA. (G) ISH of collagen type X mRNA. (H) TUNEL detection of apoptotic cells,
indicated by white arrows. Cell nuclei were counterstained with DAPI. (I) TRAP staining for chondroclasts, indicated by arrows. In all studies, results are
shown as means (n=6) 6 SD. * denotes p,0.05 comparing 1,25(OH)2D3-treated to control groups. Open squares in the images on the left represent
areas magnified in the images on the right. Abbreviations: PZ-proliferative zone, HZ-hypertrophic zone.
doi:10.1371/journal.pone.0020772.g001
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rehydrated in serial ethanol dilutions, fixed in 4% PFA, and
treated with proteinase K (4 mg/ml in 0.2 M Tris-HCl, 5 mM
EDTA, pH 7.5) for 20 min. After digestion, slides were rinsed,
fixed again and acetylated in 0.1 M triethanolamine to reduce
hydrogen bonding. RNA probes were dissolved to hybridization
buffer (10 mM Tris pH 7.5, 600 mM NaCl, 1 mM EDTA, 0.25%
SDS, 10% Dextran Sulfate (American Bioanalytical 50% solution),
16Denhardt’s, 200 mg/ml yeast tRNA (Gibco), 50% formamide)
for a final concentration of 1 mg/mL. Following overnight
hybridization at 65uC, slides were incubated with increasing
concentrations of SSC to promote denaturing of nucleic acids and
then digested with RNAse to eliminate unbound single stranded
RNA. DIG-labeled probes were detected using a polyclonal anti-
digoxigenin antibody attached to alkaline phosphatase (Roche)
which produces color response when reacts with its substrate
NBT+BCIP (Promega). Endogenous ALP was inhibited with
Levamisole (Fluka). In all hybridizations, no signal was observed
with sense probes which were used as negative controls [29].
Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick
End Labeling (TUNEL) and tartarate-resistent acid
phosphatase (TRAP)
TUNEL staining of the apoptotic cells was performed using In
Situ Cell Death Detection Kit, POD (Roche), and DNA was
counterstained with DAPI. Chondroclast invasion was assessed by
TRAP staining kit (Sigma-Aldrich). Both assays were done
according to manufacturer’s instructions.
Sample preparation and confocal laser scanning
microscopy
Femurs from the mid-shaft were transversally sectioned with a
low speed saw (IsoMet, Buehler GmbH, Du ¨esseldorf, Germany)
with an initial thickness of 200 mm. Samples were then polished by
hand from both sides until a final thickness of 80 mm. For
mechanical fixation during polishing, samples were embedded in
acrylate (Sigma-Aldrich) and glued with double-sided tape to a
polishing holder. Confocal laser scanning microscopy (CLSM) was
performed using Leica DMI4000B equiped with Leica Application
Suite software. Micrographs were taken using 106 and 436
objectives with a numerical aperture of 0.75. The excitation
wavelength for the calcein was set to 488 nm, while the emission
was measured at a range from 505 up to 530 nm. The excitation
wavelength for the alizarine complexon was set to 532 nm, with
measurement of the emission at a range from 660 up to 760 nm.
Statistical analysis
All data are expressed as mean 6 SD or SE. The significance of
differences between groups was determined using JMP 8.0
Statistical Discovery Software (SAS Institute 2000) by one-way
analysis of variance. Differences between groups were further
evaluated by Tukey-Kramer HSD test. Differences were consid-
ered significant at P,0.05.
Results
1,25(OH)2D3 reduces tibial growth plate width in young
rats
Previously, VDR activation was shown to affect growth plate
development [18,19], and induce vascular calcification [30], in
rats with chronic renal damage. To assess whether pharmacolog-
ical administration of 1,25(OH)2D3 influences bone formation in
young rats with normal renal function we established two
regiments where 1,25(OH)2D3, was administered to young rats
for a period of one week or one month. 1-week and 1-month
treatment with 1,25(OH)2D3 induced vascular calcification, as
evident by intense Alizarin Red staining of the aortae, compared
to control (Fig S1A,B). Staining of tibiae with Safranin O (stain for
cartilage) revealed marked reduction in the total growth plate
width in both experiments (Fig. 1A, 2A). Measurement of
individual zones showed that this effect is attributed predomi-
nantly to the narrowing of the hypertrophic zone of the growth
plate, since the proliferative zone width remained unchanged
(Fig. 1B, 2B). Hypertrophic zone width was reduced by 47% after
1-week 1,25(OH)2D3 treatment and 32% after 1-month treatment
compared to the relevant controls. While continuous 1-week
1,25(OH)2D3 administration did not significantly alter the
morphological appearance of chondrocytes, intermittent 1-month
treatment resulted in disordered chondrocyte morphology,
noticeably disrupting the columnar organization of the growth
plate (Fig. 2A,E). Growth plate phenotypes were not manifested in
significant tibial length differences (and final weight) between
experimental groups, suggesting presence of compensating mech-
anisms which regulate longitudinal growth in this model.
1,25(OH)2D3 induces chondrocytes proliferation and
reduces the expression of hypertrophic chondrocyte
markers
Given the unchanged width of the proliferative zone, we
subsequently tested whether 1,25(OH)2D3 altered the number of
proliferating cells. Both 1,25(OH)2D3 treatment groups showed
elevated ratio of PCNA positive cells out of the total population of
proliferating cells, increasing by 107% after 1-week treatment, and
by 131% after 1-month treatment (Fig. 1C,D, 2C,D). The count of
total proliferating cells did not significantly vary between groups.
Narrowing of the growth plate may stem from a number of
mechanisms including hindered or accelerated chondrocyte
maturation, elevated apoptosis, enhanced chondroclastogenesis
and osteogenesis [31,32]. To investigate this question, we fist
examined the expression of several chondrocyte differentiation
markers. In situ hybridization (ISH) analysis using specific probes
for aggrecan and collagen type II, major structural components of
the growth plate cartilage, demonstrated their compressed
distribution in the 1,25(OH)2D3-treated groups compared to
controls (Fig. 1E,F, 2E,F). As aggrecan and collagen type II are
normally expressed in all growth plate zones, excluding the
terminally differentiated chondrocytes [33], the effect observed is
Figure 2. 1-month intermittent administration of 1,25(OH)2D3 induces chondrocyte proliferation and compresses chondrocytes
maturation zone in young rats. 4 weeks old male Spague Dawley rats received i.p. injections of 3 mg/kg 1,25(OH)2D3 (n=6, VD) or vehicle (n=6,
Ctr) on alternating days, three times a week for a period of 30 days. (A) Safranin O staining of tibial proximal growth plates. Arrows indicate reduced
hypertrophic zone width in 1,25(OH)2D3-treated compared to the control group. (B) Width measurements of total growth plate, proliferative zone,
and hypertrophic zone. (C) Percent of PCNA positive proliferating cells out of total proliferating cell count. (D) Immunhistochemistry of PCNA positive
proliferating cells. (E) ISH of collagen type II mRNA. (F) ISH of aggrecan mRNA. (G) ISH of collagen type X mRNA. (H) TUNEL detection of apoptotic cells,
indicated by white arrows. Cell nuclei were counterstained with DAPI. (I) TRAP staining for chondroclasts, indicated by arrows. In all studies, results are
shown as means (n=6) 6 SD. *denotes p,0.05 comparing 1,25(OH)2D3-treated to control group. Open squares in the images on the left represent
areas magnified in the images on the right. Abbreviations: PZ-proliferative zone, HZ-hypertrophic zone.
doi:10.1371/journal.pone.0020772.g002
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20772Figure 3. 1,25(OH)2D3 dose and time-dependently suppresses chondrocytic differentiation of ATDC5 cells. ATDC5 cells were seeded at
equal density (5610
4 cells / well in 12 well plates) and allowed to differentiate for a period of 21 days. Treatment was initiated the following day using
1, 10, 30 nM 1,25(OH)2D3 or vehicle (control) dissolved in normal medium. (A) Light microscopy of cells treated with increasing concentrations of
1,25(OH)2D3 compared to control cells over the course of differentiation. (B) Staining with Alcian Blue (for glycosaminoglycans), Alizarin Red (for
mineral deposits), and ALP activity of 1,25(OH)2D3-treated compared to control cells (representative day 14 is shown). (C) Quantitative measurement
of secreted ALP (pNPP hydrolysis assay), glycosaminoglycans (DMB assay), and BGP (ELISA kit) in the cell media (representative day 14 is shown). (D)
Colorimetric tetrazolium salt (XTT) mitochondrial cleavage into formazan derivative assay in cells plated at indicated densities. (E) Real-time PCR
analysis of chondro-osteogenic markers: Sox9, Runx2, and collagen type II normalized to GAPDH. (F) Zymography using SDS-PAGE copolymerized
with gelatin, detecting MMP2 and MMP9 enzymatic activity in the media of 1,25(OH)2D3-treated compared to control cells. (G) Real-time PCR analysis
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areas. Whereas 1-week 1,25(OH)2D3 treatment showed equal
intensities of aggrecan and collagen type II mRNA staining
throughout the growth plate, 1-month 1,25(OH)2D3 treatment
resulted in weaker staining in the proliferative zone and more
intense staining in the hypertrophic zone chondrocytes. In this
regard, considering the observation of disrupted columnar
organization it is plausible to assume that chondrogenesis is
affected not only in the mature hypertrophic zone, but also in the
earlier stages of chondrocyte proliferation during 1-month
1,25(OH)2D3 treatment. We speculate that a combined notion
of increased PCNA staining and delayed escalation in collagen
type II, as well as aggrecan expression, points toward a
1,25(OH)2D3-meidated disruption in the differentiation balance,
favoring chondrocytes proliferation over maturation. ISH using
probe for collagen type X, a specific marker for hypertrophic
chondrocytes, supported these results, by showing a significantly
reduced area of collagen type X expression in 1,25(OH)2D3 –
treated compared to control tibiae in both groups (Fig. 1G, 2G).
These data suggest that both continuous or intermittent treatment
with 1,25(OH)2D3 augments proliferation and alters hypertrophic
maturation of growth plates chondrocytes.
1,25(OH)2D3 induces hypertrophic chondrocyte
apoptosis and suppresses chondroclast invasion
Following the observation of compressed growth plate and
diminished chondrocyte hypertrophy we investigated plausible
mechanisms which might contribute to the development of this
phenotype. TUNEL, labeling DNA strand nicks, showed that both
1-week and 1-month 1,25(OH)2D3 treatment significantly increas-
es the number of apoptotic cells in the hypertrophic zone
compared to the respective control groups (Fig. 1H, 2H). All the
TUNEL-positive cells were present in the maturation and
hypertrophic layers of the growth plate. Surprisingly, the invasion
of chondroclasts, associated with cartilage resorption, was
markedly diminished by both 1-week and 1-month 1,25(OH)2D3
–treatment regiments, as shown by TRAP staining (Fig. 1I, 2I).
These results suggest that enhanced apoptotic death, but not
enhanced chondroclastogenesis may account for the reduced
width of the growth plate hypertrophic zone.
1,25(OH)2D3 increases proliferation, while inhibiting
chondrocytic differentiation of ATDC5 cells
The foregoing observation of compressed aggrecan, collagen
type II and type X raise a possibility of direct influence of
1,25(OH)2D3 and VDR activation on chondrocytes maturation.
We tested the effect of the same formulation of 1,25(OH)2D3 used
in our animal studies on the chondrogenic profile of ATDC5 cell
line. ATDC5 are capable of undergoing differentiation and form
mineralized nodules in culture. Treatment with 1, 10, or 30 nM
1,25(OH)2D3 over the course of 21 days, inhibited the formation
of mineralized nodules in a dose-dependent manner (Fig. 3A). This
was accompanied by inhibited accumulation of proteoglycans
(GAG, Alcian Blue staining), mineral deposition (Alizarin Red
staining) and alkaline phosphatase (ALP, NBT/BCIP staining)
activity (Fig. 3B). Quantitative analysis of cell media over the
course of differentiation also revealed a significant reduction in the
secretion of ALP, GAG and Bone Gla Protein (BGP), known to be
expressed in the mature chondrocytes (Fig. 3C). Concomitant with
reduced differentiation and mineralization, 1,25(OH)2D3 treat-
ment increased the metabolic cleavage of XTT, indicative of
higher cell proliferation, over a range of cell densities (Fig. 3D).
mRNA levels of key transcription factors Sox 9, Runx 2, mRNA of
Collagen type II, as well as mRNA and enzymatic activity of the
matrix metalloproteinases MMP2 and MMP9, measured by
gelatin-zymography, were all downregulated by 1,25(OH)2D3 in
a dose and time dependent manner throughout differentiation
(Fig. 3E, F, G). Overall, in accordance with the in vivo observations,
these in vitro data point toward positive effect on the proliferation
and negative effect on the maturation of chondrocytes by
1,25(OH)2D3 treatment.
1-week and 1-month 1,25(OH)2D3 administration
reduced cortical bone thickness and elevated porosity
To our knowledge the effects of 1,25(OH)2D3 on young bone
during rapid growth under normal physiological conditions were
not previously examined using high-resolution imaging technolo-
gies. In this study we used microcomputed tomography (micro-
CT) technique to evaluate whether alterations in the growth plate
coincided with alterations in three-dimentional bone structure. 1-
week administration of 1,25(OH)2D3 resulted in 14% lower
cortical bone thickness (Co.Th.) compared to control, and the
effect exacerbated to 45% reduction after 1-month 1,25(OH)2D3
treatment (Fig. 4A,C, 5A,C). No significant changes in the total
cross-sectional area (T.Ar.), cortical bone area (Ct.Ar.) and
medullary area (M.Ar.) were observed after 1-week administration,
whereas 1-month 1,25(OH)2D3 group showed 28% reduction in
Ct.Ar and 22% increase in the M.Ar, indicating thinner cortical
femurs. Notably, 1,25(OH)2D3 triggered a significant reduction in
bone volume over total volume (BV/TV) which fell to 7% lower
than control during 1-month regimen. As BV/TV represents the
relative ratio between bone and open space, the reduction BV/TV
resulted in reciprocal 138% elevation in the percent cortical
porosity (Ct.Po.) after 1-week (BV/TV of VD 96.9% compared to
Ctr 98.6%) and 416% elevation after 1-month (BV/TV of VD
91.5% compared to Ctr 98.3%) 1,25(OH)2D3 treatment (Fig. 4C,
5C). Comparison of Ct.Po. between the bones of the control
groups showed no significant differences, indicating unchanged
bone volume and pore volume fractions over three week growth
time. The total volume of pores increased by 117% after 1-week
1,25(OH)2D3 and by 295% after 1-month 1,25(OH)2D3, whereas
the number of closed pores ((Po.N.(cl)), which accounts for small
fraction of total pores, escalated from 258% to 400% higher than
the respective control groups (Fig. 4C, 5C). The presence of
1,25(OH)2D3-elevated cortical pores is evident in the 3D model
representations, indicated by arrows (Fig. 4A,E, 5A,E). These
observations point toward a negative influence of 1,25(OH)2D3 on
bone quality, starting from 1-week administration and intensifying
by 1-month exposure.
1,25(OH)2D3 1-week administration increases trabecular
bone, which is comparable to control after 1-month
treatment
1-week 1,25(OH)2D3 administration triggered significant in-
creases of 68% in BV/TV, 77% in trabecular number (Tb.N.),
and 5% in trabecular thickness (Tb.Th.), while causing a
corresponding 54% reduction in the trabecular separation
(Tb.Sp.) compared to control (Fig. 4B). Analysis of trabecular
of MMP2 and MMP9 normalized to GAPDH. In all studies, results are shown as means (n=3) 6 SD. * denotes p,0.05 comparing 1,25(OH)2D3-treated
to control cells. Abbreviations: AU-Arbitrary Units.
doi:10.1371/journal.pone.0020772.g003
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differences between 1,25(OH)2D3-treated or vehicle-treated
groups (Fig. 5B). Interestingly, the 1,25(OH)2D3-induced acceler-
ation in trabecular bone formation during 1-week treatment,
resulted in bone profile similar to one month control. The fact that
1-month 1,25(OH)2D3-treatment did not further enhance bone
formation, may arise from yet to be indentified, restricting
mechanisms which exert negative-feedback regulation, character-
istic to many endocrine systems. These results imply that
1,25(OH)2D3 enhances trabecular bone modeling, correlating to
the increased apoptosis observed at the level of hypertrophic zone
chondrocytes.
1,25(OH)2D3 inhibits cortical bone formation and
mineralization
Micro-CT analysis of cortical mineral density (BMD) demon-
strated significant 1062% and 2262% reduction during 1-week
and 1-month 1,25(OH)2D3 treatments respectively. In attempt to
elucidate the reasons for 1,25(OH)2D3-increased cortical porosity
and reduced BMD, we monitored the dynamics of bone formation
by injecting two fluorochromes, calcein and alizarin complexone
at different time points, known to bind precipitated mineral.
Confocal microscopy images showed progressive time dependent
bone deposition (first green calcein and subsequently red alizarine
complexone) leading to pore closure in the control group
(Fig. 6A,B). 1-week treatment with 1,25(OH)2D3 demonstrated
markedly reduced fluorochrome staining, particularly surrounding
pore area indicating hampered bone formation and thus reduced
pore closure. Bone apposition at the periosteal side does not
appear to be affected, supported by the unchanged T.Ar. values
(Fig. 4C, 5C). These data suggest that larger percentage of pores
observed during 1,25(OH)2D3 administration results from re-
pressed bone formation in the interior and the endosteal side of the
cortical bone of young growing rats.
Discussion
To our knowledge, the current study is the first to utilize 3D
imaging for presenting differential effects of supraphysiological
doses of 1,25(OH)2D3 on the trabecular and cortical bone
architecture in healthy young rats. We have shown that both 1-
week-continuous and 1-month-intermittent administration of
1,25(OH)2D3 results in significantly narrower growth plates,
influencing chondrocytes proliferation, maturation and apoptosis.
Alterations in growth plate morphology coincide with changes in
bone architecture, transiently elevated trabecular bone and
suppressed cortical bone formation, which exacerbated with
prolonged 1,25(OH)2D3 administration. Overall, our results
suggest that high pharmacological doses of 1,25(OH)2D3 may
directly hamper endochondral ossification and appositional bone
development in the growing skeleton.
Longitudinal bone growth is largely dependent on the
cartilaginous growth plates, where chondrocytes proliferate in a
columnar manner, hypertrophy and undergo subsequent replace-
ment by primary spongiosa, constituting mineralized trabecular
bone. Any condition or interruption of this orderly transition can
lead to bone deformities and decline the growth potential [31].
Children and animals with vitamin D deficiency or VDR
mutations have expanded growth plates, known as rickets, which
are largely corrected by high calcium diet [1,3]. Aberrant growth
plate, however, appears before the onset of hypocalcemia in VDR-
deficient mice [34], supporting a defined role for 1,25(OH)2D3 in
the process of endochondral bone formation. Recent literature
supports both systemic (mineral homeostasis centered) and local
(VDR-mediated activity in chondrocytes and osteoblasts) of
1,25(OH)2D3. Whereas most studies examine the effect of
1,25(OH)2D3 in transgenic models or in conjunction with either
nephrectomy or ovariectomy, we tested the effect of pharmaco-
logical 1,25(OH)2D3 administration on growth plate development
under normal physiological conditions. Our observations of
1,25(OH)2D3–mediated compression of hypertrophic chondro-
cytes, are in line with the data from VDR or 1a-hydroxylase
deficient animals, where hypertrophic chondrocyte zone spreads
in a rickets-like manner [3,35]. Moreover, the restricted
chondrocytes hypertrophy associated with TUNEL-detected
apoptotic death in our models correlates with the above studies,
where growth plate expansion was reported to be secondary to the
decreased apoptosis. Although, the width of the proliferative layer
was not altered, 1,25(OH)2D3 treatment caused an increase in the
number of the proliferative cells both in vivo and in the ATDC5
chondrocytic cell line in vitro. On the other hand, analysis of
maturation markers, including Collagen type II and X, revealed
down-regulation by 1,25(OH)2D3 in the ATDC5 and compressed
expression in the rat growth plates. In this regard, a collection of
in-vitro findings previously showed differential effect of
1,25(OH)2D3 on the proliferation and differentiation of a variety
of chondrocytic cell types, where the responsiveness depends on
the state of maturation, dose and the time course of treatment
[31,36]. A study in uremic rats also showed that both daily and
intermittent calcitriol therapy actively enhance markers of
chondrocyte proliferation (cyclin D, histone-4, mTOR) and the
expression of the Fibroblast Growth Factor Receptor-3 (FGFR3),
a known chondrogenesis inhibitor localized to the hypertrophic
zone, compared to the nephrectomized control [18]. In contrast to
our observations, however, the same study reported higher
expression level of VDR, Calcium Receptor (CaR), Fibroblast
Growth Factor-23 (FGF-23) associated with hypertrophic chon-
drocytes. This discrepancy could possibly arise from the important
role VDR, CaR and FGF-23 play in the maintenance of calcium
and phosphorus homeostasis which is strongly perturbed in the
model of renal failure. Overall, we speculate that our observations
result from the direct stimulatory influence of 1,25(OH)2D3 on
Figure 4. 1-week administration of 1,25(OH)2D3 alters cortical bone architecture by reducing thickness and elevating porosity, and
trabecular parameters by increasing number and thickness in young rats. 4 weeks old male Spague Dawley rats received daily i.p.
injections of 1 mg/kg 1,25(OH)2D3 (n=6, VD) or vehicle (n=6, Ctr) for a period of 7 days. Femurs were removed and subjected to m-CT scan from
proximal femoral metaphysis to the mid-point of diaphysis using 13.4 mm pixel size resolution and 3500 ms laser exposure. (A) 3D images of cortical
bones. Note the reduced cortical thickness and elevated porosity in the 1,25(OH)2D3-treated group, marked by green arrow. (B) 3D images of
trabecular bones. Note the markedly increased trabecular number in the 1,25(OH)2D3-treated group. (C) Cortical morphological parameters: total
cross-sectional area (Tt.Ar.), cortical bone area (Ct.Ar.), medullary area (M.Ar.), cortical thickness (Co.Th.), bone volume over total volume (BV/TV),
percent cortical porosity (Ct.Po.), total volume of pores (Po.V.) and number of closed pores (Po.N.(cl)). (D) Trabecular bone morphological parameters:
bone volume over total volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th.), trabecular separation (Tb.Sp.). Results are showna s
means (n=6) 6 SE. * denotes p,0.05 comparing 1,25(OH)2D3-treated to control group. (E) 3D images of total scan cut by coronal plane (marked red).
Note the higher presence of pores in the cortical bone of 1,25(OH)2D3-treated group compared to control group, marked by green arrow.
doi:10.1371/journal.pone.0020772.g004
Effect of 1,25(OH)2D3 on Growth Plate and Bone
PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e20772Figure 5. 1-month administration of 1,25(OH)2D3 alters cortical bone, but not trabecular bone, architecture by reducing thickness
and elevating porosity in young rats. 4 weeks old male Spague Dawley rats received i.p. injections of 3 mg/kg 1,25(OH)2D3 (n=6, VD) or vehicle
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chondrocyte maturation or induction of the neighboring bone-
residing osteoblasts to dominate the process of osteogenesis over
chondrogenesis.
In attempt to translate the altered proliferation and differenti-
ation from the level of growth plate to the level of bone modeling,
we subjected bones to micro-CT analysis. By comparison, 1-week
1,25(OH)2D3 administration resulted in trabecular bone state
analogous to the three weeks older, 1-month control group.
Despite similar growth plate phenotype, 1-month 1,25(OH)2D3
administration did not further enhance trabecular bone develop-
ment, possibly due to additional mechanisms controlling bone
growth capacity. Such anabolic effects of active vitamin D were
previously reported following 13 day infusion of 1,25(OH)2D3 to
adult rats, manifested by increased trabecular osteoid mass.
Moreover, in accordance with our data, histomorphometric
analysis showed significantly reduced number of surface osteo-
clasts, suggesting lower bone resorption of the newly formed bone
[37]. Additional study where high dose of 1,25(OH)2D3 was given
to adult female rats resulted in augmented osteoblast recruitment
and performance, reduced osteoclast number and stimulated
trabecular bone remodeling [38]. Interestingly, VDR2/2,1 a-
hydroxylase2/2 or double mutant mice on rescue diet show
reduced bone formation below wild-type, which is corrected by
1,25(OH)2D3, indicating physiological anabolic role for the
endogenous 1,25(OH)2D3 mediated by VDR in vivo [39,40].
Although, not tested here, the inhibitory effects of calcitriol on
TRAP-positive osteoclast and chondroclast invasion may involve a
mechanism of suppressed PTH release, well associated with bone
resorption. Alternatively, 1,25(OH)2D3 may directly influence
osteoclasts, since ex vivo studies reported a calcitriol VDR-mediated
suppression of osteoclast differentiation from precursor cells,
dependent on c-Fos protein reduction [41]. Additional supporting
evidence relates to the impaired chondrocytes activity, which was
previously shown to locally regulate osteoclastogenesis during bone
formation [7]. Collectively, our results suggest that 1,25(OH)2D3-
mediated increase in chondrocyte proliferation together with
compressed maturation and enhanced apoptosis, indicate acceler-
ated process of growth plate transition which ultimately results in
increased osteogenesis.
A particularly interesting observation came from the analysis of
cortical bone which in contrast to trabecular bone, portrayed a
reduced osteogenesis profile, in terms of both architecture and
mineral content. Separate from the longitudinal bone growth,
appositional bone growth relies on the process of modeling where
endosteal osteoclast resorb inner cortex surface and periosteal
osteoblasts deposit and mineralize primary bone matrix on the
outer perimeter [42]. Our results demonstrated that continuous or
intermittent treatment with 1,25(OH)2D3 reduce cortical model-
ing, leaving bones 14% and 45% thinner after 1-week and 1-
month treatment respectively. Increased medullar area in
conjunction with normal cortical perimeter point toward uncou-
pled bone formation and resorption, plausibly stemming from
enhanced osteoclastic activity at the endosteal surface. Previous
(n=6, Ctr) on alternating days, three times a week for a period of 30 days. Femurs were removed and subjected to m-CT scan from proximal femoral
metaphysis to the mid-point of diaphysis, using 13.4 mm voxel size resolution and 4000 ms laser exposure. (A) 3D images of cortical bones. Note the
reduced cortical thickness and elevated porosity in the 1,25(OH)2D3-treated group compared to control, as indicated by green arrows. (B) 3D images
of trabecular bones. (C) Cortical morphological parameters. (D) Trabecular bone morphological parameters. For abbreviations see figure 4. Results are
shown as means (n=6) 6 SE. * denotes p,0.05 comparing 1,25(OH)2D3-treated to control group. (E) 3D images of total scan cut by coronal plane
(marked red). Note the reduced thickness and higher presence of pores in the cortical bone of 1,25(OH)2D3-treated group compared to control group,
as indicated by green arrows.
doi:10.1371/journal.pone.0020772.g005
Figure 6. 1-week administration of 1,25(OH)2D3 suppresses intracortical mineral deposition in young rats. 4 weeks old male Spague
Dawley rats received daily i.p. injections of 1 mg/kg 1,25(OH)2D3 (n=6, VD) or vehicle (n=6, Ctr) for a period of 7 days. Both groups also received i.p.
injections of mineral binding fluorochromes, 40 mg/kg calcein (green) on day 2 and 20 mg/kg alizarin complexon (red) on day 5. Femurs were
removed, mid-diaphysis segments transversally cut into 200 mm sections, embedded acrylate and polished until a final thickness of 80 mm. Samples
were mounted on glass slides and subjected to LSCM. (A) 106magnification. White arrows point to the fluorochrome binding surrounding cortical
pores. Note the markedly impaired mineral deposition in the 1,25(OH)2D3-treated group compared to the control group. (B) 436 magnification.
Representative images from n=3 in each group are shown.
doi:10.1371/journal.pone.0020772.g006
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doses of 1,25(OH)2D3 markedly increase RANKL expression by
osteoblast, stimulating cortical osteoclastogenesis and bone
resorption in rats [43]. Moreover, daily calcitriol injection in
uremic rats was reported to result in lower cortical thickness,
compared to nephrectomized control [20]. These data partially
support the fact that cortical bone is affected more dramatically
during renal failure than trabecular bone, in the pediatric patients
on peritoneal dialysis and calcitriol therapy [9]. Inside the cortex,
the coupling between osteoblast and osteoclast activity is
manifested in the presence of cortical pores which provide
conduits for the passage of neurovascular structures. Cortical
porosity is considered to be closely associated with mechanical
properties of cortical bone, influencing bone strength and risk of
fracture. We showed that 1-week 1,25(OH)2D3 administration
dramatically augmented the volume and number of cortical pores,
which exacerbated to over 4 fold higher percent cortical porosity
in relation to control upon 1-month administration. Since larger
medular cavity implies enhanced osteoclast presence, we speculate
that elevated bone resoprtion, either alone or in combination with
suppressed osteoblast function, accounts for higher porosity. A
recent notion of two distinct osteoblast types situated in the cortical
bone [44], raises another possibility, whereby 1,25(OH)2D3
selectively suppresses the intracortical osteoblasts lining primary
osteons, without affecting surface mesenchymal osteoblasts lining
the periosteum. Finally, analysis of mineral binding flurochromes
demonstrated that administration of 1,25(OH)2D3 dramatically
hampered intracortical collagen matrix deposition and minerali-
zation leading to the deficient filling of pores. Previous literature
reports using classical 2D histomorphometric methods show
inhibitory effect of pharmacological dose of 1,25(OH)2D3 on
cortical bone remodeling in ribs of adult dogs [45] and impaired
mineralization in adult rats [37]. Our observations suggest that
although osteoblast-dependent radial cortical growth was not
affected, 1,25(OH)2D3 augmented endosteal osteolclast activity and
largely disturbed intracortical bone remodeling and mineralization.
To offset the 1,25(OH)2D3-related ABD and cardiovascular
components of CKD, novel less hypercalcemic analogues of
vitamin D, including paricalcitol and doxercalciferol, have already
been available for use in adult patients [10]. In light of the
significant adverse effects of calcitriol, search for alternative
treatments in CKD-MBD which ensure optimal growth plate
physiology and resolution of secondary hyperparathyroidism
without the burden of systemic vasculopathy are in place.
Supporting Information
Figure S1 1,25(OH)2D3 induces vascular calcification in
the aortae of young rats. 4 weeks old male Spague Dawley rats
were treated with either 1 mg/kg 1,25(OH)2D3 (n=6, VD) for a
period of 1 week or with 3 mg/kg 1,25(OH)2D3 (n=6, VD) three
times a week for a period of 1 month. Control groups were treated
according to the same respective schedules with vehicle (n=6 in
each control group). Descending aortae were embedded in
paraffin blocks, cut into 5 mm sections and subjected to histological
analysis. (A) Alizarin Red (stain for mineral deposition) of aortae in
1 week 1,25(OH)2D3 experiment. (B) Alizarin Red staining of
aortae in 1 month 1,25(OH)2D3 experiment. Abbreviations: L-
lumen, M-media, A-adventitia. Green arrows point toward the
diffuse calcification of the aortic media and the neighboring blood
vessel. Note that adventitia does not stain red and remains
unmineralized.
(TIF)
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